Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Healthy Volunteer
Interventions: MT-201; Drug
Lead sponsor: Mirador Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
Interventions: tocilizumab-aazg (TYENNE); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parenchymous Tissue Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Surgicel®; Biological · Device
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more

Conditions: Mental Health Issue, HIV, Substance Use
Interventions: Single Session Narrative Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Epinephrine, Hypersensitivity, Immediate, Anaphylaxis
Interventions: Epinephrine Nasal Spray, 2.5 mg, Epinephrine Nasal Spray, 5.25 mg; Drug
Lead sponsor: Hikma Pharmaceuticals USA Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Marlton, New Jersey • Salt Lake City, Utah

Conditions: Venous Thromboembolism
Interventions: dalteparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 17
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more

Conditions: Neurosciences
Interventions: Behavioral testing during neuronal recordings; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Prostate Cancer
Interventions: MDX-010 / MDX-010 + Docetaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 11
States / cities: Tucson, Arizona • Long Beach, California • San Diego, California + 7 more

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Interventions: Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 6 Months to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Healthy
Interventions: LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Survivorship
Interventions: Behavioral Activation, Supportive Psychotherapy; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: Oprozomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more

Conditions: Pediatric Cancer, Survivorship
Interventions: No intervention- registry only; Other
Lead sponsor: Giselle Sholler; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2032
U.S. locations: 18
States / cities: Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more

Conditions: Neoplasms
Interventions: letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 3 more

Conditions: Irritant Contact Dermatitis
Interventions: Skin Testing of Hair cleansing products; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Asthma
Interventions: FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 21
States / cities: Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more

Conditions: Hypertension, Diabete Type 2
Interventions: Treatment as Usual Plus Occupational Therapy, Treatment as Usual; Behavioral
Lead sponsor: University of Indianapolis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: AUTO3; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Miami, Florida + 4 more

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: Insulin Resistance
Interventions: Neuromuscular Electrical Stimulation (Sensory), Neuromuscular Electrical Stimulation, Resistance Training; Device · Other
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions: Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Active Ulcerative Colitis
Interventions: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida

Conditions: Cancer
Interventions: Trametinib tablet, Trametinib pediatric formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Scottsdale, Arizona • Nashville, Tennessee

Search by objective public record fields.

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Single Session Narrative Therapy Study

Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Studying the Neuronal Basis of Human Social Cognition

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

A Study of LY3484356 in Healthy Female Participants

A Study of Brief Behavioral Activation for the Treatment of Depression in Older Adult Cancer Survivors

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Beat Childhood Cancer Specimen Banking and Data Registry

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Effect of Occupational Therapy in Promoting Medication Adherence

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Interaction With HIV Antiretroviral Agents

Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation